Bronchiolitis, Viral
Conditions
Brief summary
Background. Viral bronchiolitis is a common cause of hospitalization for acute respiratory insufficiency in young infants. Despite several RCT have tested the effectiveness of various agents, currently there is no proven specific therapy for bronchiolitis, treatment remaining mostly supportive. Based on available studies, exogenous surfactant replacement in bronchiolitis is likely to have a promising safety and efficacy profile. Primary objective. To evaluate whether Curosurf treatment is effective compared to placebo (air) in reducing the duration of invasive mechanical ventilation in the first 14 days of hospitalization, in infants less than 12 months suffering from acute hypoxemic bronchiolitis. Methods. a multicenter, double-blind, placebo-controlled, randomized trial. 19 Italian PICUs will enroll children less than12 months with hypoxemic acute bronchiolitis, with need for invasive mechanical ventilation. Once the patient has been recruited, randomization should occur as quickly as possible. The first dose of Curosurf or placebo should be administered within 60 minutes of randomization. The treatment may be repeated once, not before 12 hours and not later than 24 hours after the initial dose. The assignment of the type of treatment will be communicated by the Coordinator center to the researcher attending the patient's bed. The same medical researcher will then take care of administering the assigned treatment, masking the procedure with appropriate precautions, for example with screens or closing the patient's room whenever possible. The preparation and administration of treatment, medication or placebo, can be done by a nurse who must not disclose the assigned treatment and will not be involved in the patient's care until the conclusion of the study. Patient evaluation will be carried out by other physicians and/or nurses who will not be aware of the assigned treatment. Regardless the received treatment, all patients will be assisted according to standard practice of the Unit. For the purposes of the study, several parameters will be collected 15 minutes before, and 2, 6, 12, 24, 36, 48 hours after administration of the drug: oxygenation indexes such as OI, OSI, PaO2 and SatO2; Invasive ventilation parameters, i.e. current volume, positive end expiratory pressure, peak pressure, respiratory rate, FiO2 and mean airway pressure; and ventilation indexes such as PaCO2 and End Tidal CO2. If it is necessary to repeat the treatment, the above parameters will be re-collected with the same timepoints. During the study all the AE/ADR will be recorded.
Interventions
DRUGCurosurf 80Mg/Ml Intratracheal Suspension
CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
OTHERAmbient Air
Ambient air aspirated in sterile syringes
Sponsors
Azienda Ospedaliera Universitaria Integrata Verona
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
Patient's parents and the doctors/nurses responsible for the patient's care will be blinded. At each center only a physician and a nurse will know and prepare the drug or placebo, being subsequently not clinically involved in the care of that particular patient. The assignment of the type of treatment will be communicated by the Coordinator centre in an individual way and reserved to the researcher attending the patient's bed. The same medical researcher will then take care of administering the treatment assigned to the patient, masking the procedure with appropriate precautions. The preparation and administration of treatment can be done with the help of a nurse who does not have to disclose the type of treatment assigned. Thereafter, such a nurse will not be involved in the patient's care until the conclusion of the study. The patient evaluation will be carried out by other physicians and/or nurses who will not be aware of the type of treatment carried out.
Intervention model description
multicenter, double-blind, placebo-controlled, randomized trial
Eligibility
Sex/Gender
ALL
Age
40 Weeks to 12 Months
Healthy volunteers
No
Inclusion criteria
1. Aged \> 40 weeks (correct gestational age) and \< 12 months. 2. Patient intubated and mechanically ventilated for at least 6 hours, with expected requirement of ventilatory support of at least 24 hours. 3. Clinical picture strongly suggestive for acute bronchiolitis (fever of probable viral origin, fine crackles, prolonged expiration, lung hyperexpansion on chest X-ray) 4. Moderate or severe pediatric acute respiratory distress syndrome, defined by a Oxygenation Index (OI) \> 8 or an Oxygen Saturation Index (OSI) \> 7.5 5. Written informed consent obtained from both parents
Exclusion criteria
1. Severe prematurity (gestational age \< 32 weeks). Patients with gestational age less than 32 weeks will be excluded because they are considered at high risk for respiratory pathology following their severe prematurity. This consideration does not apply in successive gestational ages. Therefore patients with mild prematurity, i.e. with gestational age equal to or greater than 32 weeks, are not to be excluded. 2. Recent phase of oxygen dependency (need for oxygen supplementation to maintain satO2 \> 94% in the four weeks preceding hospitalization in Pediatric ICU) 3. Invasive mechanical ventilation for more than 24 hours. 4. Oxygenation index (OI) \> 30 5. Cyanotic congenital heart disease 6. Untreated pneumothorax 7. Neuromuscular diseases 8. Severe Neurological Alterations 9. Other severe congenital anomalies 10. Indication not to attempt resuscitation 11. Patient already recruited for other clinical studies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of days free from invasive mechanical ventilation | day 14 | Number of days free from invasive mechanical ventilation within the first 14 days of hospitalization. Ventilation-free days will start after the first successful extubation (at least 48 hours without the need for re-intubation) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of days free from non-invasive mechanical ventilation in the post-extubation phase | day 14 | Number of days free from non-invasive mechanical ventilation in the post-extubation phase |
| Number of cases requiring new intubation | day 14 | Number of cases requiring new intubation after previous extubation in 14 days from randomization. |
| Number of days of patients in PICU | day 14 | Number of days of patients in PICU |
| Number of days of hospitalization | day 14 | Number of days of hospitalization. |
| Number of days free from oxygen supplementation | day 14 | Number of days free from oxygen supplementation |
| Values of the mechanical ventilation parameter (MAP) during invasive mechanical respiratory support | detected 15 minutes before administration of treatment and at a distance of 2, 6, 12, 24, 36 and 48 hours | Changes in the ventilatory parameter (MAP) during invasive mechanical respiratory support |
| Number of patients undergoing a repeated treatment (Curosurf or placebo) | within 24 hours of the first treatment | Number of patients undergoing a repeated treatment (Curosurf or placebo). The repetition of the assigned treatment may take place at least 12 hours apart and in any case within 24 hours of the first treatment, at the same dosage and with the same method of administration |
| Number of patients undergoing unconventional or more invasive treatments (HFOV, Nitric Oxide, ECMO) | during the first 14 days | Number of patients undergoing unconventional or more invasive treatments (HFOV, Nitric Oxide, ECMO) |
| Rate of deaths | (1) Mortality during the first 14 days of hospitalization (2) Mortality from the date of the first intervention until the date of hospital discharge | Rate of deaths before hospital discharge |
| Number of serious desaturation episodes, severe bradycardia, extreme bradycardia or cardiac arrest, pulmonary hemorrhage, pneumothorax | within the first 48 hours after treatment | Number of serious desaturation episodes (SatO2 \< 75%), episodes of severe bradycardia (FC \< 80/min) , episodes of extreme bradycardia or cardiac arrest with the need for chest compressions and/or administration of drugs for resuscitation, episodes of pulmonary hemorrhage, episodes of pneumothorax |
| Values of the Oxygen Saturation Index (OSI) | detected 15 minutes before administration of treatment and at a distance of 2, 6, 12, 24, 36 and 48 hours | Changes in the Oxygen Saturation Index (OSI) |
Countries
Italy
Outcome results
None listed